Challenges in the management of bone tumors - 1996

Annals of the New York Academy of Sciences

Volumn 824, Issue , 1997, Pages 167-179

  Craft, Alan W ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; LIPOSOME; MESNA; METHOTREXATE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; TOPOTECAN; VINCRISTINE;

BONE TUMOR; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; ENCAPSULATION; EWING SARCOMA; FEASIBILITY STUDY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; OSTEOSARCOMA; PATIENT CARE; PROGNOSIS; TREATMENT PLANNING;

EID: 0030726367     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb46219.x     Document Type: Conference Paper

References (34)

1. STILLER, C. A. 1988. Centralisation of treatment and survival rates for cancer. Arch. Dis. Child. 63: 23-30.
2. STILLER, C. A. 1994. Population based survival rates for childhood cancer in Britain. Br. Med. J. 309: 1612-1616.
3. KALETSCH, U., P. KAATSCH & J. MICHAELIS. Jahresbericht 1995 des Deutschen Kinderkrebsregisters, Mainz, 1996.
4. MEYERS, P. A. et al. 1992. Chemotherapy for nonmetastic osteogenic sarcoma: The Memorial Sloan-Kettering Experience. J. Clin. Oncol. 10: 5-15.
5. BRAMWELL, V. H. C. 1987. Chemotherapy of operable osteosarcoma. Bailliere's Clin. Oncol. 1: 175-195.
6. BRAMWELL, V. H. C. et al. 1992. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup. J. Clin. Oncol. 10: 1579-1591.
7. SOUHAMI, R. L. et al. 1996. A randomised trial of two regimens of chemotherapy in operable osteosarcoma. A study of the European Osteosarcoma Intergroup. Proc. Am. Soc. Clin. Oncol. 15: 520.
8. ROSEN, G. et al, 1981. Osteogenic sarcoma: Eighty-percent three-year disease free survival with combination chemotherapy (T-7). Nat. Cancer Inst. Monogr. 56: 213-220.
9. WINKLER, K. et al. 1984. Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a German/Austrian study. J. Clin. Oncol. 2: 617-624.
10. DELEPINE, H. et al. 1989. Individualisation de posologie de Methotrexate haut dose par le dosage des concentrations plasmatique interet therapeutique dans le sarcome osteogenique. Bull Cancer (Paris) 76: 913-918.
11. DELEPINE, N. et al. 1989. High value of pharmacokinetics (PK) adaptation in success of treatment of osteosarcomas (OS) by protocols based on high dose methotrexate (HDMTX). Proc. Am. Soc. Clin. Oncol. 8: 319. (Abstr.)
12. GRAF, K. et al. 1994. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J. Clin. Oncol. 12: 1443-1451.
13. GOUGETTE, A., A. APCHIN, M. FOKA & J. M. RICHARDS. 1986. Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients. Eur. J. Cancer Clin. Oncol. 22: 257-263.
14. CHUANG, V. P. et al. 1981. The therapy of osteosarcoma by intra-arterial cis-platinum and limb preservation. Cardiovasc. Intervent. Radiol. 4: 229-235.
15. JAFFE, N. et al. 1985. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J. Clin. Oncol. 3:1101-1104.
16. WINKLER, K. et al. 1990. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (Study COSS-86). Cancer 66: 1703-1710.
17. DODWELL, D. J., H. GURNEY & N. THATCHER. 1990. Dose intensity in cancer chemotherapy. Br. J. Cancer 61: 789-794.
18. REDMOND, C., B. FISHER & W. H. SAMUEL. 1983. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat. Rep. 67: 519.
19. SMITH, M. A. et al. 1991. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J. Natl. Cancer Inst. 83: 1460-1470.
20. ORNADEL, D. et al. 1994. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: Phase II trial of the European Osteosarcoma Intergroup. J. Clin. Oncol. 12: 1842-1848.
21. HARRIS, M. B. et al. 1995. Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A Pediatric Oncology Group Study. Med. Pediatr. Oncol. 24: 87-92.
22. MACEWEN, E. G. et al. 1989. Therapy of osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl-tripeptide. J. Natl. Cancer Inst. 81: 935-938.
23. VERWEIJ, J. et al. 1994. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcoma of the adult. An EORTC Soft Tissue and Bone Sarcoma Group Study. Eur. J. Cancer 30A: 842-843.
24. HOUGHTON, P. et al. 1992. Evaluation of 9-dimethylaminomethyl-10-hydroxy camptothecin against xenografts derived from adult and childhood tumors. Cancer Chemother. Pharmacol. 31: 229-239.
25. TUBERGEN, D. et al. 1994. Phase I study of topotecan in children with refractory solid tumors: A pediatric oncology group study. Proc. Am. Soc. Clin. Oncol. 13: 463.
26. DAVIS, A. M., R. S. BELL & P. J. GOODWIN. 1994. Prognostic factors in osteosarcoma: A critical review. J. Clin. Oncol. 12: 423-431.
27. CRAFT, A. W., S. COTTERILL & J. IMESON. 1993. Improvement in survival for Ewing's sarcoma by substitution of ifosfamide for cyclophosphamide. Am. J. Pediatr. Hematol. Oncol. 15(Suppl. A): S31-S35.
28. JURGENS, H. et al. 1988. Multidisciplinary treatment of Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61: 23-32.
29. NESBIT, M. E. et al. 1990. Multimodal therapy of primary nonmetastatic Ewing's sarcoma of bone: Along termfollow-up of the first intergroup study. J. Clin. Oncol. 8:1664-1674.
30. JURGENS, H. et al. 1988. The GPO Cooperative Ewing's Sarcoma Studies CESS 81/86 Report after 6 1/2 years. Klin. Paediatr. 200: 243-252.
31. OBERLIN, O. et al. 1992. No benefit of ifosfamide in Ewing's sarcoma: A nonrandomized study of the French Society of Pediatric Oncology. J. Clin. Oncol. 10: 1407-1412.
32. KAMEN, B. A. E. FRENKEL & O. M. COLVIN. 1995. Ifosfamide: Should the honeymoon be over? J. Clin. Oncol. 13: 307-309.
33. SKINNER, R. et al. 1996. Risk factors for ifosfamide nephrotoxicity in children. Lancet 348: 578-580.
34. BURDACH, S. et al. 1993. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J. Clin. Oncol. 11: 1482-1488.